Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
With a deal clinched for US generic major Mylan Inc. to buy a portion of Abbott Laboratories’s branded generic business, industry watchers now have their eyes riveted on how it will affect the established drug market in Japan, seeing Pfizer…
To read the full story
Related Article
- Mylan Japan Offers Severance Package for 110 Sales Reps
March 29, 2016
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
BUSINESS
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
- Nipro Pharma Recalls Topical Drugs over Long-Running Manufacturing Deviations
July 16, 2026
- JCR to File DMD Drug Givinostat in Japan by End-2026
July 16, 2026
- Daiichi Sankyo Healthcare to Take Over Claritin EX Sales in Japan
July 16, 2026
- Maruishi Set to Secure Japan Rights to Kringle’s Vocal Fold Scar Drug
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…